European Association of Urology. Prostate Cancer. 2020 15th January 2021]; Available at: https://uroweb.org/guideline/prostate-cancer/.

Ost P. Reynders D. Decaestecker K. et al.

Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter Phase II trial.

J Clin Oncol. 36: 446-453Phillips R. Shi W.Y. Deek M. et al.

Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial.

JAMA Oncology. 6: 650-659Tree A.C. Khoo V.S. Eeles R.A. et al.

Stereotactic body radiotherapy for oligometastases.

The Lancet Oncology. 14: e28-e37

Clinicaltrials.gov. ClinicalTrials.gov identifier NCT03569241, PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM). 2018 19/08/2019]; Available at: https://clinicaltrials.gov/ct2/show/NCT03569241.

De Bleser E. Jereczek-Fossa B.A. Pasquier D. et al.

Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy.

European Urology. 76(6): 732-739Lépinoy A. Silva Y.E. Martin E. et al.

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.

European Journal of Nuclear Medicine and Molecular Imaging. 46: 40-48Supiot S. Rio E. Pacteau V. Mauboussin M.H. Campion L. Pein F.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

BMC Cancer. 15: 646Bauman G. Ferguson M. Lock M. et al.

A Phase 1/2 Trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer.

Int J Radiat Oncol Biol Phys. 92: 856-862Murthy V. Gupta M. Mulye G. et al.

Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer.

Clinical Oncology. 30: 442-447Musunuru H.B. D'Alimonte L. Davidson M. et al.

Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life.

Int J Radiat Oncol Biol Phys. 102: 1438-1447Pinitpatcharalert A. Happersett L. Kollmeier M. et al.

Early tolerance outcomes of stereotactic hypofractionated accelerated radiation therapy concomitant with pelvic node irradiation in high-risk prostate cancer.

Advances in radiation oncology. 4: 337-344Dearnaley D. Syndikus I. Mossop H. et al.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The Lancet.

Oncology. 17: 1047-1060Miralbell R. Roberts S.A. Zubizarreta E. Hendry J.H.

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy.

Int J Radiat Oncol Biol Phys. 82: e17-e24Vogelius I.R. Bentzen S.M.

Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials.

Int J Radiat Oncol Biol Phys. 100: 858-865Widmark A. Gunnlaugsson A. Beckman L. et al.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Lancet. 394: 385-395

The linear-quadratic model and implications for fractionation.

Clinical Oncology. 31: 673-677Syndikus I. Cruickshank C. Staffurth J. et al.

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018).

Clinical and translational radiation oncology. 25: 22-28The Royal College of Radiologists; Society and College of Radiographers; Institute of Physics and Engineering in Medicine

On target: ensuring geometric accuracy in radiotherapy.

The Royal College of Radiologists, London, UK

ClinicalTrials.gov Identifier: NCT01368588, Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer.

Bethesda (MD): National Library of Medicine, (USA) ()De Bruycker A. De Bleser E. Decaestecker K. et al.

Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates.

European Urology. 75: 826-833Hall W.A. Paulson E. Davis B.J. et al.

NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer.

Int J Radiat Oncol Biol Phys. 109: 174-185Gay H.A. Barthold H.J. O'Meara E. et al.

Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas.

Int J Radiat Oncol Biol Phys. 83: e353-e362Yi S.K. Mak W. Yang C.C. et al.

Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of radiation-induced lumbosacral plexopathy.

Int J Radiat Oncol Biol Phys. 84: 376-382

American Association of Physicists in Medicine. Stereotactic body radiation therapy: The report of AAPM Task Group 101. 2010 [Accessed 21st January 2021]; Available at: https://www.aapm.org/pubs/reports/detail.asp?docid=102.

Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite.

Br J Radiol. 85: 1279-1286Nahum A. Sanchez-Nieto B.

Tumor control probability modelling: Basic principles and applications in treatment planning.

Phys Med. 17: 13-23Dearnaley D.P. Jovic G. Syndikus I. et al.

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Lancet Oncol. 15: 464-473

Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method.

Int J Radiat Oncol Biol Phys. 16: 1623-1630

Complication probability as assessed from dose-volume histograms.

Radiat Res Suppl. 8: S13-S19Burman C. Kutcher G.J. Emami B. Goitein M.

Fitting of normal tissue tolerance data to an analytic function.

Int J Radiat Oncol Biol Phys. 21: 123-135Michalski J.M. Gay H. Jackson A. Tucker S.L. Deasy J.O.

Radiation dose-volume effects in radiation-induced rectal injury.

Int J Radiat Oncol Biol Phys. 76: S123-S129Kneebone A. Hruby G. Ainsworth H. et al.

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.

Eur Urol Oncol. 1: 531-537Siva S. Bressel M. Murphy D.G. et al.

Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial.

European Urology. 74: 455-462Ost P. Jereczek-Fossa B.A. Van As N. et al.

Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences.

Clin Oncol (R Coll Radiol). 28: e115-e120Fodor A. Berardi G. Fiorino C. et al.

Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate.

cancer. 119: 406-413Picchio M. Berardi G. Fodor A.

(11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.

Eur J Nucl Med Mol Imaging. 41: 1270-1279Schick U. Jorcano S. Nouet P. et al.

Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.

Acta Oncol. 52: 1622-1628Ost P. Decaestecker K. Lambert B. et al.

Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate.

cancer. 74: 297-305Vaugier L. Palpacuer C. Rio E. et al.

Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07).

Int J Radiat Oncol Biol Phys. 103: 1061-1067Frykholm G.J. Sintorn K. Montelius A. Jung B. Påhlman L. Glimelius B.

Acute lumbosacral plexopathy during and after preoperative radiotherapy of rectal adenocarcinoma.

Radiother and Oncol. 38: 121-130Peeters K.C. van de Velde C.J. Leer J.W. et al.

Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study.

J Clin Oncol. 23: 6199-6206Kirkpatrick J.P. van der Kogel A.J. Schultheiss T.E.

Radiation Dose-Volume Effects in the Spinal Cord.

Int J Radiat Oncol Biol Phys. 76: S42-S49Nieder C. Milas L. Ang K.K.

Tissue tolerance to reirradiation.

Semin Radiat Oncol. 10: 200-209Abusaris H. Hoogeman M. Nuyttens J.J.

Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region.

Technol Cancer Res Treat. 11: 591-597Murray L.J. Lilley J. Hawkins M.A. Henry A.M. Dickinson P. Sebag-Montefiore D.

Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review.

Radiother Oncol. 125: 213-222Paradis K.C. Mayo C. Owen D. et al.

The Special medical physics consult process for reirradiation patients.

Advances in radiation oncology. 4: 559-565Smith T. O'Cathail S.M. Silverman S. et al.

Stereotactic body radiation therapy reirradiation for locally recurrent rectal cancer: outcomes and toxicity.

Adv Radiat Oncol. 5: 1311-1319Loi G. Fusella M. Lanzi E. et al.

Performance of commercially available deformable image registration platforms for contour propagation using patient-based computational phantoms: A multi-institutional study.

Med Phys. 45: 748-757Murray L.J. Lilley J. Thompson C.M. et al.

Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.

Int J Radiat Oncol Biol Phys. 89: 406-415